Drug and gene delivery
Nonviral Gene Editing
Nanotherapeutics manufacturing
Biomaterials for regenerative medicine
The problem
Over 50% of patients are nauseous on GLP-1 injections, and needles for life are unsustainable.
Despite GLP-1s proven benefits, many patients churn due to side effects or painful delivery.
Our platform
A convenient nasal spray delivering the same drug with similar efficacy.
Our underlying nanoparticle technology can also expand to a broader class of peptides and other biologics in the future for respiratory or neurological use cases.
Our opportunity
A massive market exceeding $100B+ in a few years.
Besides nausea, the nose-to-brain (N2B) delivery also enables new neurological indications such as addiction or dementia that are being explored for GLP-1s.
Robin Guo
CEO & Co-Founder
Professor Kam Leong
Inventor & Co-Founder
Dr. Huiyi Liang
Founding Senior Scientist
Professor Edward X. Guo
Scientific Advisor
Latest in GLP-1s and health peptides.
Subscribe to our newsletter and cut through the fat.
Disclaimer
The information on this website relates to early-stage, preclinical research and is intended for scientific and informational purposes only. Findings described here are based on studies conducted in animal models and have not been evaluated in human clinical trials. These results may not translate to humans. Nothing on this site is intended to diagnose, treat, cure, or prevent any disease, and no claims are made regarding the safety or efficacy of any product, therapy, or technology in humans. Any statements about potential applications are exploratory and forward-looking, not guarantees of future results.This content has not been evaluated by the FDA or any other regulatory body, and no product referenced here is approved for human use or commercially available. Statements on this website should not be construed as medical advice, investment advice, or an offer to sell any product or service.